Patiromer (trade name: Veltassa) has been approved in Germany since July 2017 for the treatment of hyperkalemia in adults.
In hyperkalemia, blood potassium levels are too high. Potassium is found in various foods. It plays an important role in maintaining essential physical processes in the body. These include the normal activity of nerves and muscles, as well as the regulation of the balance of fluids.
If the kidneys don’t flush out enough potassium, potassium levels rise. Several things can cause this to happen: diseases such as chronic kidney failure, adrenal insufficiency (Addison's disease), or various medications – especially those for the treatment of heart failure or high blood pressure. While a slight increase usually won’t cause any problems, very high levels of potassium can be fatal. Symptoms include muscle weakness and even paralysis or arrhythmia.
The drug patiromer binds potassium in the gastrointestinal (stomach and bowel) tract in order to decrease blood potassium levels.
Patiromer is available as a powder in three different doses:
- 8.4 g
- 16.8 g
- 25.2 g
The powder is mixed with about 80 ml of water, apple juice or cranberry juice, and taken with a meal. The recommended dose at the start of treatment is 8.4 g per day. Depending on blood potassium levels, the dose can be increased up to 25.2 g daily. The powder should not be used within three hours of taking other medication.
Several treatments are available for patients with hyperkalemia. The treatment will depend on various factors such as underlying diseases, whether it is an initial treatment or which treatments have been tried before. A change in diet may also be an option. The treatment is individually adjusted by the doctor.
In 2018, the Institute for Quality and Efficiency in Health Care (IQWiG, Germany) looked into whether patiromer has any advantages or disadvantages in adults with hyperkalemia when compared with individually optimized treatment.
But the manufacturer did not provide any suitable data with which to do the assessment.
This information summarizes the main results of a review produced by the Institute for Quality and Efficiency in Health Care (IQWiG, Germany). The review was commissioned by the German Federal Joint Committee (G-BA) as part of the “early benefit assessment of medications.” On the basis of this review and the hearings received, the G-BA passed a resolution on the added benefit of patiromer (Veltassa).
Institute for Quality and Efficiency in Health Care (IQWiG, Germany). Patiromer (hyperkalaemia) – Benefit assessment according to §35a Social Code Book V. Dossier assessment; Commission A18-21. June 27, 2018. (IQWiG reports; Volume 639).
IQWiG health information is written with the aim of helping
people understand the advantages and disadvantages of the main treatment options and health
Because IQWiG is a German institute, some of the information provided here is specific to the German health care system. The suitability of any of the described options in an individual case can be determined by talking to a doctor. informedhealth.org can provide support for talks with doctors and other medical professionals, but cannot replace them. We do not offer individual consultations.
Our information is based on the results of good-quality studies. It is written by a team of health care professionals, scientists and editors, and reviewed by external experts. You can find a detailed description of how our health information is produced and updated in our methods.